Viking Therapeutics, Inc. (VKTX) News
Track canonical SquawkNews coverage tagged to VKTX, Viking Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 50 indexed stories across 17 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks
Shares of Viking Therapeutics (VKTX) extended their losing streak to three sessions on Monday as the company confirmed that it completed stock and convertible-note offerings that raised nearly $548 million in net proceed
EQUITY | Sep 29, 2026, 03:03 AM UTC
L
Viking Therapeutics Raises $547.8 Million via Equity Sale and 2.00% Convertible Notes
Viking Therapeutics completed twin capital raises, securing approximately $547.8 million in combined net proceeds. The company sold 7,857,143 common shares at $35.00 per share, with the underwriters fully exercising thei
EQUITY | Sep 28, 2026, 09:36 PM UTC
L
Viking Therapeutics (VKTX) Closes Upsized Stock and 2.00% Convertible Notes Offerings, ~$575M Gross
Viking Therapeutics closed upsized offerings of 9,035,714 shares at $35.00 and $258.75M of 2.00% notes due 2032, with full over-allotments exercised, for gross proceeds of about $575.0M and estimated net proceeds of abou
EQUITY | Sep 28, 2026, 08:30 PM UTC
L
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
Gross Proceeds to Viking Approximately $575 MillionSAN DIEGO, Sept. 28, 2026 // -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for me
EQUITY | Sep 28, 2026, 08:30 PM UTC
L
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
NEW YORK, Sept. 28, 2026 // -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ:VKTX) breached their fiduciary duties to sha
NEWS | Sep 28, 2026, 03:12 PM UTC
L
Weekly Recap: $500M raise and VANQUISH—1/2 fully enrolled
Viking Therapeutics, Inc. (NASDAQ:VKTX) bolstered its balance sheet with about $500M from equity and $225M of convertible notes to advance VK2735 and VK3019, reporting fully enrolled Phase III subcutaneous VK2735 trials
NEWS | Sep 28, 2026, 11:08 AM UTC
H
Bulls and Bears: Costco, KB Home, McDonald’s
examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. U.S. stocks ended the week higher, with the Nasdaq Composite leading gains as renewed enthusiasm f
LIVE | Sep 26, 2026, 12:00 PM UTC
H
S&P 500 Erases Losses as US, Iran Reportedly Discuss Hormuz Deal: Stock Market Today
The S&P 500 clawed back most of its morning decline at midday Thursday after sources told Reuters that U.S. and Iranian negotiators meeting in New York are discussing a phased deal that would have Tehran reopen the Strai
LIVE | Sep 24, 2026, 05:32 PM UTC
H
Crude Oil Rises Over 4%; Darden Earnings Miss Views
U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 350 points on Thursday. The Dow traded down 0.70% to 51,153.35 while the NASDAQ dipped 0.70% to 26,746.39. The S&P 500 also fell, d
LIVE | Sep 24, 2026, 04:02 PM UTC
L
VKTX Stock Heads Toward Worst Day In Over A Year Just Days After Promising Weight Loss Drug Data — Here’s What’s Driving The Selloff
Shares of Viking Therapeutics (VKTX) fell more than 12% in pre-market trading on Thursday, putting them on track for their worst session in more than a year, after the biotech firm priced an upsized stock and convertible
EQUITY | Sep 24, 2026, 12:51 PM UTC
H
Stitch Fix Posts Mixed Q4 Results, Joins Viking Therapeutics And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Thursday. Shares of Stitch Fix Inc (NASDAQ: SFIX ) fell sharply in pre-market trading after the company reported mixed fourth-
LIVE | Sep 24, 2026, 12:02 PM UTC
L
Viking Therapeutics Share Drop After Upsized Stock, Notes Offerings
By Chris WackShares of Viking Therapeutics shares fell after the company said it has priced concurrent public offerings of 7.9 million shares at $35 a share, and $225 million of 2.00% convertible senior notes due 2032.Th
EQUITY | Sep 24, 2026, 11:44 AM UTC
L
Viking Therapeutics, Inc. (VKTX) Prices Upsized $500M Stock and 2.00% Convertible Notes
Viking priced 7,857,143 shares at $35 for ~$275M and $225M of 2.00% convertible notes due 2032; initial conversion price is ~$50.75. Closings expected Sept. 25, 2026, subject to conditions.Material DetailsContext by AI A
EQUITY | Sep 24, 2026, 11:06 AM UTC
L
Viking Therapeutics Prices Upsized $500M Offering of Common Stock and Convertible Sr Notes
Viking Therapeutics Prices Upsized $500M Offering of Common Stock and Convertible Sr Notes
EQUITY | Sep 24, 2026, 11:05 AM UTC
L
VKTX - Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes
VKTX - Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes
EQUITY | Sep 24, 2026, 11:05 AM UTC
H
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket
Shares of GlucoTrack Inc (NASDAQ: GCTK ) rose sharply in pre-market trading following the announcement that its subsidiary, Lokahi Therapeutics, signed its first external, fee-for-service partnership. Innovate GBM, a non
LIVE | Sep 24, 2026, 09:05 AM UTC
L
VKTX Stock Eyes Blockbuster Week Despite Share Offering — Retail Traders See A Stronger Hand In Buyout Talks
Shares of Viking Therapeutics (VKTX) are heading for their best weekly run in over two years as promising data for its weight-loss drug VK2735 outweighs, for now, investor unease over a proposed share offering and renewe
EQUITY | Sep 24, 2026, 02:24 AM UTC
L
VKTX Stock Slides After-Hours On $400M Stock-And-Notes Raise After Tuesday’s Rally
Shares of Viking Therapeutics (VKTX) fell sharply by 9% after-hours on Wednesday after the company said it plans to raise about $400 million through stock and convertible notes.VKTX finished regular trading at $41.65, up
EQUITY | Sep 23, 2026, 10:56 PM UTC
L
Viking Therapeutics Announces Proposed Offerings Of Common Stock And Convertible Senior Notes
Viking Therapeutics, Inc. NASDAQ:VKTX
EQUITY | Sep 23, 2026, 09:14 PM UTC
L
Viking Therapeutics Shares Fall on $200M Offerings of Stock, Notes
By Elias SchisgallShares of Viking Therapeutics fell after the biopharmaceutical company said it plans to offer $200 million each of common stock and convertible senior notes due 2032.Shares fell 8.2% to $38.24 in after-
EQUITY | Sep 23, 2026, 09:10 PM UTC
L
Viking Therapeutics, Inc. (VKTX) Plans $200M Equity, $200M Convertible Notes Offerings
Viking Therapeutics plans public offerings of $200M common stock and $200M convertible senior notes due 2032, each with a 30-day underwriters’ option for up to $30M more, subject to market and other conditions.Material D
EQUITY | Sep 23, 2026, 08:34 PM UTC
L
VKTX - Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes
VKTX - Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes
EQUITY | Sep 23, 2026, 08:33 PM UTC
L
Viking Therapeutics Price Target Raised to $87.00/Share From $83.00 by Truist Securities
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 04:31 PM UTC
L
Truist Securities maintains Buy rating on Viking Therapeutics, $87 price target
Truist Securities maintained their Buy rating on Viking Therapeutics's stock with a price target of $87.00.The price target implies an upside of 113.0% from the Sep 22 close of $40.85.Key takeaways from the analyst noteS
EQUITY | Sep 23, 2026, 04:20 PM UTC
L
Key facts: VKTX starts VK2735 Phase 3; 12—week GI safety equals placebo
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
NEWS | Sep 23, 2026, 07:15 AM UTC
L
VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?
A sharp rally in Viking Therapeutics (VKTX) has put its obesity drug VK2735 back in the spotlight, with the stock pulling ahead of Eli Lilly (LLY) and Novo Nordisk (NVO) as investors weigh whether Viking could one day dr
EQUITY | Sep 23, 2026, 02:23 AM UTC
M
Lilly rises after Viking reports maintenance-dosing weight-loss preservation
Lilly shares rose 0.8% to $1,174.37 Tuesday after Viking Therapeutics reported maintenance-dosing results for VK2735, with patients preserving up to 97% of prior weight loss.
EQUITY | Sep 22, 2026, 09:41 PM UTC
M
VKTX shares jump after early obesity-injection data optimism
Viking Therapeutics said early data for VK2735 (obesity injection) suggested most patients kept most weight off with every-other-week dosing or monthly dosing; Oppenheimer raised its target amid optimistic Wall Street co
EARNINGS | Sep 22, 2026, 08:31 PM UTC
M
Viking Therapeutics stock jumps premarket on obesity-drug data
Viking Therapeutics climbed more than 35% in premarket trading after new data suggested patients on its experimental obesity drug VK2735 preserved much of their weight loss even after switching to less frequent dosing sc
EQUITY | Sep 22, 2026, 03:11 PM UTC
H
On Holding, Viking Therapeutics, Shopify And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Nasdaq Composite gaining over 1% on Monday. Shares of On Holding AG (NYSE: ONON ) rose sharply after the company affirmed its FY26 sales guidance above estimates and issued third-quarter
LIVE | Sep 22, 2026, 02:25 PM UTC
M
VKTX jumps after VK2735 shows weight-loss maintenance on reduced dosing
Viking Therapeutics said VK2735 helped patients maintain most weight loss when moved from once-weekly dosing to every-other-week dosing.
EARNINGS | Sep 22, 2026, 12:08 PM UTC
L
Viking Therapeutics shares jump on maintenance study top-line results
Viking Therapeutics said it has positive top-line results from a maintenance study of its weight-loss drug; the stock rose 39% to $41.85 in premarket on Tuesday.
EARNINGS | Sep 22, 2026, 11:34 AM UTC
L
VKTX - UP TO 97% WEIGHT LOSS MAINTAINED WITH EVERY-OTHER-WEEK DOSING FOR THREE MONTHS
VKTX - UP TO 97% WEIGHT LOSS MAINTAINED WITH EVERY-OTHER-WEEK DOSING FOR THREE MONTHS
NEWS | Sep 22, 2026, 11:29 AM UTC
L
VKTX - Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
VKTX - Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
NEWS | Sep 22, 2026, 11:13 AM UTC
M
Viking Therapeutics GLP-1 obesity drug shows 22% weight loss
Viking Therapeutics said its experimental GLP-1 obesity drug helped patients lose 22% of body weight after 33 weeks of weekly treatment in a maintenance study.
EQUITY | Sep 22, 2026, 11:12 AM UTC
M
VKTX, GPCR, ALT stocks jump after Novo Nordisk M&A signal
Novo Nordisk said it could pursue larger acquisitions while targeting more than five “multi-blockbuster” launches by 2030, lifting smaller obesity players: Viking Therapeutics gained nearly 4%, Structure Therapeutics ros
EQUITY | Sep 22, 2026, 05:29 AM UTC
H
What's Going On With the Dip in Viking Therapeutics Stock?
Viking Therapeutics Inc. (NASDAQ: VKTX ) shares are dropping Tuesday amid a broader risk-off session, even though the stock’s longer-term uptrend and its sector’s strength both remain intact. Viking Therapeutics shares a
LIVE | Sep 15, 2026, 07:28 PM UTC
L
VKTX: Obesity program VK2735 advances in phase III with broad market and manufacturing strategies
Lead obesity candidate VK2735 is advancing through phase III trials in both injectable and oral forms, with maintenance and dosing flexibility studies underway. Manufacturing capacity and commercialization strategies are
NEWS | Sep 14, 2026, 08:59 PM UTC
L
VKTX: Obesity program VK2735 advances in phase III with broad market and manufacturing strategies in place
Lead obesity candidate VK2735 is advancing through phase III trials in both injectable and oral forms, with maintenance studies exploring less frequent dosing for improved patient adherence. Manufacturing and commerciali
NEWS | Sep 14, 2026, 08:26 PM UTC
L
VKTX - Viking Therapeutics to Participate at Upcoming Investor Conferences
VKTX - Viking Therapeutics to Participate at Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 08:05 PM UTC
L
VKTX edges higher in August ahead of Q3 obesity-drug data
VKTX shares edged higher in August ahead of early-stage obesity-drug data release in Q3.
EQUITY | Sep 01, 2026, 12:23 AM UTC
H
VKTX Maintains Outperform
VKTX Q2 solidifies obesity strategy
EQUITY | Jul 30, 2026, 12:44 PM UTC
L
VKTX Viking Therapeutics RESULTS: Q2, Q2 EPS $-1.1 vs. EST $-1.25, Q2 Income from operations $-132.597M vs. EST $-150.3M, Q2 Net Income $-12
VKTX Viking Therapeutics RESULTS: Q2, Q2 EPS $-1.1 vs. EST $-1.25, Q2 Income from operations $-132.597M vs. EST $-150.3M, Q2 Net Income $-128.022M vs. EST $-144.7M, Q2 operating expenses $132.597M
EARNINGS | Jul 29, 2026, 08:09 PM UTC
L
VKTX - Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
VKTX - Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EARNINGS | Jul 29, 2026, 08:06 PM UTC
L
VKTX Reiterate Buy with PT $95 as upcoming maintenance readout could guide Ph.3 Extensions and enhance VK2735 Commercial competitiveness @ S
VKTX Reiterate Buy with PT $95 as upcoming maintenance readout could guide Ph.3 Extensions and enhance VK2735 Commercial competitiveness @ Stifel
EQUITY | Jul 24, 2026, 11:24 AM UTC
L
VKTX Maintain Buy and $107 PT as Preview VK2735 maintenance study data read-out @ Canaccord
VKTX Maintain Buy and $107 PT as Preview VK2735 maintenance study data read-out @ Canaccord
EQUITY | Jul 15, 2026, 01:03 PM UTC
L
How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?
2026-07-05 01:25:00 ET Viking Therapeutics (NASDAQ: VKTX) is a challenger in the obesity drugs go
EQUITY | Jul 05, 2026, 05:26 AM UTC
L
Here's Why Viking Therapeutics Stock Surged Higher in June
2026-07-03 09:45:39 ET Viking Therapeutics (NASDAQ: VKTX) stock rose by 19.2% in
EQUITY | Jul 03, 2026, 01:46 PM UTC
M
VKTX Advances Weight-Loss Drug
Viking Therapeutics initiates Phase 1 trial for VK3019, a dual amylin and calcitonin receptor agonist for weight loss
EQUITY | Jun 24, 2026, 01:05 PM UTC
L
VKTX Initiates Phase 1 Study
Viking Therapeutics initiates Phase 1 study to evaluate novel amylin receptor agonist VK3019 in healthy adults
EQUITY | Jun 24, 2026, 11:05 AM UTC